Category
Evidence & Quality Guides
Product identity, evidence-boundary and analytical-quality explainers.
-
Evidence & Quality Guides
AOD-9604 Evidence Boundary: GH Fragment Biology, Failed Development and Lot Identity
-
Evidence & Quality Guides
CJC-1295 With DAC: Albumin Binding, Identity Controls and FDA Safety Context
-
Evidence & Quality Guides
CJC-1295 Without DAC: Sequence, Naming and a Quality Checklist
-
Evidence & Quality Guides
Survodutide Research Status: Dual Glucagon/GLP-1 Biology, Trials and Material Identity
-
Evidence & Quality Guides
SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters
-
Evidence & Quality Guides
MK-677 / Ibutamoren: Clinical Status, Heart-Failure Signal and Material Questions
-
Evidence & Quality Guides
Ipamorelin Evidence and Safety: Route-Specific Data and Peptide Characterization
-
Evidence & Quality Guides
GHK-Cu Topical vs Injectable Evidence: A Route-Specific Quality Boundary
-
Evidence & Quality Guides
LL-37 Evidence Boundaries: Endogenous Peptide, Engineered Delivery and Catalog Material
-
Evidence & Quality Guides
MOTS-c “Human”: What the Label Means, and What FDA Says Is Still Missing